NYSE:NHWK NightHawk Biosciences (NHWK) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free NHWK Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range$0.26▼$0.5052-Week Range N/AVolume173,100 shsAverage Volume97,242 shsMarket Capitalization$10.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get NightHawk Biosciences alerts: Email Address Ad DTIHow you can target big results without spending big money!While most folks are paying $500… $1,000… Or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options on the market… I’m talking about the $0.25 Cent Trades! Click here so I can share the details of my $0.25 Cent Trades About NightHawk Biosciences Stock (NYSE:NHWK)NightHawk Biosciences, Inc., an integrated biopharmaceutical company, develops, manufactures, and commercializes medical countermeasures that combat unmet and emerging biothreats. The company develops ANTHIM (obiltoxaximab), a monoclonal antibody antitoxin for the treatment of inhalational anthrax. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.Read More Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here NHWK Stock News HeadlinesMarch 19, 2024 | globenewswire.comScorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major UniversityMarch 19, 2024 | americanbankingnews.comNightHawk Biosciences (NYSE:NHWK) Share Price Crosses Below 200 Day Moving Average of $0.47March 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionMarch 14, 2024 | globenewswire.comScorpius Holdings Accepted as a Member of the US Government's BioMaP-ConsortiumMarch 12, 2024 | globenewswire.comScorpius Holdings, Inc. Announces Closing of Public OfferingMarch 8, 2024 | globenewswire.comScorpius Holdings, Inc. Announces Pricing of Public OfferingMarch 7, 2024 | globenewswire.comScorpius Holdings, Inc. Announces Proposed Public Offering of Common StockMarch 7, 2024 | globenewswire.comScorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023March 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 7, 2024 | globenewswire.comScorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023February 13, 2024 | uk.finance.yahoo.comScorpius Holdings, Inc. (SCPX)February 7, 2024 | msn.comNightHawk Biosciences Debuts SCPX Ticker on NYSE AmericanFebruary 7, 2024 | msn.comNightHawk Biosciences Unveils New Name and TickerJanuary 31, 2024 | msn.comNightHawk Biosciences Strikes Key Licensing and Financing DealsJanuary 30, 2024 | finance.yahoo.comNightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing NoteJanuary 25, 2024 | finance.yahoo.comNightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical ProgramJanuary 17, 2024 | finanznachrichten.deNightHawk Biosciences: NightHawk's Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New ClientJanuary 16, 2024 | finance.yahoo.comNightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New ClientJanuary 11, 2024 | msn.comNHWK: Transformational ChangesJanuary 8, 2024 | msn.comNightHawk Biosciences changing name to Scorpius, ticker to SCPXJanuary 8, 2024 | finance.yahoo.comNightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMOJanuary 3, 2024 | finance.yahoo.comNightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National UniversityDecember 21, 2023 | finance.yahoo.comNightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research UniversityDecember 19, 2023 | msn.comNightHawk Biosciences files for $200M mixed securities shelfDecember 18, 2023 | finance.yahoo.comNightHawk Biosciences Announces Major Milestone with Completion of Manufacturing Run for a Premier U.S.-Based Biopharmaceutical CompanyDecember 12, 2023 | finance.yahoo.comNightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core AssetsDecember 3, 2023 | morningstar.comNightHawk Biosciences Inc NHWKSee More Headlines Receive NHWK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NightHawk Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today3/28/2024Next Earnings (Estimated)3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:NHWK CUSIPN/A CIK1476963 Webwww.nighthawkbio.com Phone919-240-7133FaxN/AEmployees77Year Founded2008Profitability EPS (Most Recent Fiscal Year)($1.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,440,000.00 Net Margins-2,333.27% Pretax Margin-2,546.97% Return on Equity-91.62% Return on Assets-56.48% Debt Debt-to-Equity Ratio0.27 Current Ratio0.99 Quick Ratio0.99 Sales & Book Value Annual Sales$6.38 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.82 per share Price / BookN/AMiscellaneous Outstanding Shares26,080,000Free Float21,935,000Market Cap$10.78 million OptionableOptionable Beta0.19 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Jeffrey Alan Wolf J.D. (Age 61)Founder, Chairman of the Board, CEO & President Comp: $842.6kMr. William L. Ostrander (Age 56)CFO & Secretary Comp: $476.24kDr. Justin Stebbing FRCPFRCPath, M.A., M.D., Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory BoardColonel George E. Peoples Jr.F.A.C.S., M.D., Chief Medical AdvisorMs. Ania SzymanskaHead of QualityKey CompetitorsImunonNASDAQ:IMNNMonopar TherapeuticsNASDAQ:MNPRAkari TherapeuticsNASDAQ:AKTXCadrenal TherapeuticsNASDAQ:CVKDASLAN PharmaceuticalsNASDAQ:ASLNView All CompetitorsInstitutional OwnershipSimplex Trading LLCSold 1,000 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions NHWK Stock Analysis - Frequently Asked Questions Should I buy or sell NightHawk Biosciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NightHawk Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" NHWK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NHWK, but not buy additional shares or sell existing shares. View NHWK analyst ratings or view top-rated stocks. When is NightHawk Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our NHWK earnings forecast. How were NightHawk Biosciences' earnings last quarter? NightHawk Biosciences, Inc. (NYSE:NHWK) issued its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by $0.01. The biopharmaceutical company had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.57 million. NightHawk Biosciences had a negative trailing twelve-month return on equity of 91.62% and a negative net margin of 2,333.27%. When did NightHawk Biosciences' stock split? NightHawk Biosciences shares reverse split before market open on Friday, December 11th 2020. The 1-7 reverse split was announced on Thursday, December 10th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 11th 2020. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. Who are NightHawk Biosciences' major shareholders? NightHawk Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). View institutional ownership trends. How do I buy shares of NightHawk Biosciences? Shares of NHWK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NHWK) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NightHawk Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.